Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
sam, thank you...
Ancestry Informative Markers were culled from a screen of 50,000 SNPs using Beckman and Affymetrix platforms and used with new likelihood methods to cost-effectively estimate IGAA for reference and clinical samples
Press Releases - Archive
2006
December 4, 2006
H. Lee Moffitt Cancer Center & Research Institute Licenses the Rosetta Resolver® Gene Expression Analysis System from Rosetta Biosoftware
Rosetta Biosoftware Integrates Affymetrix GeneChip® Operating Software (GCOS) with the Rosetta Resolver® System Version 5.0
I'm beyond "shy 'unt scared"...eom
sam, sam, sam, seriously,...post a link..TIA
SAM, You're killin' me..!!!!eom
ez..I'm not sure we have enough zinc to galvenize all the nails to meet the company's quota for 2nd quarter 2007. What do you think?
clog, stupid is..as...stupid does..eom
slog...sad..sad..eom
BUGGER OFF!!...FOOL.FROG!!EOM
SAM! MOOOOORE....eom
FROGCLOWN, WHAT HAPPENED TO YOU??? CAN YOU PLEASE POST YOUR OBJECTIONS TO ACQUIRING THIS STOCK? YOU HAVEN'T POSTED ONE YET, THAT HAD ANY VALIDITY. THANKS, JOHNNY
Big-Gooch, I thought you bought in? Not 3 party...thanks
It's gotta be tough being you, frogclown. Can you post "ONE"...just one.....just one...come'on......ONE POST, BIG GUYYY!!!!!!!......that has anything to do with DNAPRINTS' prospectives?
Obviously you can't...so....................sad...so..................sad..
Frogclown, particulate your opinion sir.eom
I feel 'da chiggah...
Lessee covenants to pay the Lessor as annual rent for the Leased Premises
the sum of Seventy-two thousand Dollars ($72,000.00) ("Rent") per annum,
http://sec.edgar-online.com/2006/08/07/0001231742-06-000573/Section6.asp
In addition, we anticipate that new laboratory and computer equipment will be
purchased during 2006. Computer purchases for programming, modeling and business
use are estimated at approximately $100,000 and scientific and business programs
and software at approximately $50,000. Capital expenditures for laboratory
equipment are estimated at approximately $250,000 during 2006.
http://209.85.165.104/search?q=cache:m9yY3tXuI4AJ:sec.edgar-online.com/2006/04/26/0001231742-06-0002...
STOCKHOLDER, DON'T YOU DARE TELL ME ABOUT THE "NEW LIGHT"....
slogscreaming, explain the capabilities of EPOFUION II, please..TIA
William S. Dalton, Ph.D., M.D.
President/Chief Executive Officer and Center Director
Dr. Dalton has been involved in cancer research for two decades and has authored or co-authored numerous articles in journals such as Cancer Research, Blood, Immunity, and the Journal of Biochemistry. He serves, or has served, on the editorial boards of Clinical Cancer Research, Molecular Cancer Therapeutics, Archives of Internal Medicine, Leukemia, American Journal of Oncology Review, and Investigational New Drugs. His research interests include biochemical mechanisms of drug resistance and new drug discovery. He is also an expert in the biology and treatment of multiple myeloma. Dr. Dalton played a major role in obtaining the Molecular Oncology (MOPP) grant for $5,000,000 for Moffitt Cancer Center in 2000.
http://www.moffitt.org/site.aspx?spid=FA62A8A40B6C4BB6A7821F6332A735FE
Melphalan/Topotecan: Through collaboration with the Moffitt Cancer Research Center in Tampa, FL, we are investigating the genetic basis of Melphalan/Topotecan (MT) response in multiple myeloma patients.
http://www.dnaprint.com/welcome/productsandservices/pharmaceuticals/
Executive Leadership - Timothy Yeatman
Timothy Yeatman, M.D.
Executive Vice President Translational Research,
President & CSO M2Gen Research Bios
Other Executive Bios
Biographical Information
Education: Emory University – M.D.; Surgical Internship & Residency at the University of Florida; Surgical Oncology Fellowship at the MD Anderson Cancer Center.
http://www.moffitt.org/Site.aspx?spid=1CA57470F656415A99F51F3ADA4A7E04
Excellent post Ann. We've been involved since 2001...further substantiating our integral part in the upcoming collaboration. Thanks, again..
Hong-Gang Wang, Ph.D.
Associate Professor in the Interdisciplinary Oncology Program
Member-in-Residence of the Moffitt Cancer Center
http://cancerbio.hsc.usf.edu/wang.html
AWARDS
Florida High Tech Corridor
2001 - 2002 USF "External Matching Grant" Project Awards
Wang, Hong-Gang. "A model system for cancer pharmacogenomics." Grant Amount: $99,000. Partner companies: DNAPrint Genomics.
Layman's Abstract: DNA print genomics is enabling the medical application of human population genomics to help prevent, define and diagnose disease. With the University of South Florida will develop a cell based model system to determine the variable response to two widely used anti-cancer compounds. The resulting product will constitute a powerful tool for developing genomics-based pharmaco-predictive tolls that will form the foundation of the emerging personalized medical market.
http://www.research.usf.edu/ed/01awards.htm
sam, Amazing that DnaPrint could pick up Kenna for 1.5 million shares. The basis for EPOFUSION.
Kenna Technologies has demonstrated the utility of BoneFusion through a pilot study that explored different dosing and administration schedules for teriparatide (Parathyroid hormone, 1-34), a new drug under clinical development for the treatment of osteoporosis.
Kenna's pilot study, to be released shortly, describes the application of BoneFusion in testing the efficacy of treatment that can be achieved with varied dosing and administration regimens of teriparatide.
"This is the beginning of a stream of important drug discovery and clinical development insights produced with in silico simulations at Kenna. Our proprietary know-how and methods for rigorous fusion of knowledge together with our ability to rapidly develop executable simulations of very complex human biology is proven.
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH.
Massachusetts General Hospital and Harvard Medical School, Boston, USA.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&list_uids=11346808&cmd=Retrieve&...
frankly frog....frog, frankly...if other models were capable of:
"It will play a valuable role in our Company's efforts to pursue the development of drugs which maximize efficacy and minimize side effects by tailoring medications for specific individuals and well-defined population sectors."
...there would not be a DnaPrint Genomics.
But since I am 100% sure there is a company......
Ancestry, slog..Ancestry...Ancestry....Ancestry...Ancestry + EPOFUSION II......get it yet?..
DNAPrint Genomics Acquires Kenna Technologies
Key Processes Will Enable Development of Personalized Medicine or 'Theranostics' Using Test/Drug Combinations
SARASOTA, FL -- (MARKET WIRE) -- November 01, 2005 -- DNAPrint™ genomics, Inc. (OTC BB: DNAG), a developer of genomics-based products and services, today announced that it has acquired Kenna Technologies, Inc., of West Chester, Pa., a private company which builds computer models that mimic complex biological systems.
Under terms of the agreement, Kenna's shareholders exchanged all of the company's outstanding shares for 1.5 million shares of DNAPrint genomics Common Stock. The transaction was effective on Tuesday, Oct. 25, 2005.
"The acquisition of Kenna and its computational biology process, provides substantial synergies with our pharmacogenomics applications," stated Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint genomics. "We believe Kenna's technologies will lead to shorter and less expensive drug development times, and represent a powerful tool in our company's search to develop programs for personalized medicine, and test/drug combinations targeting a specific group of patients."
Computational biology models (also called In silico technology,) incorporate the vast datasets and fragmented knowledge of experimentalists and can be a crucial requirement when developing effective therapies and diagnostic products.
"Initially, the Kenna team will support the clinical development of DNAPrint's PT-401 Super EPO erythropoietin dimer for the treatment of anemia and renal failure," stated Kenna co-founder Barbara Handelin, Ph.D, who joins DNAPrint as Director of Diagnostics and General Manager of Computational Biology. "We will provide simulations to help design optimal clinical trials with respect to dosing, patient selection factors and trial duration."
As a result of the acquisition, DNAPrint also gains access to Kenna's BoneFusion™ and CellCycleFusion™ models. BoneFusion simulates the processes in bone remodeling that underlie diseases like osteoporosis, while CellCycleFusion simulates the molecular pathways that control basic cellular functions. These pathways are common targets of current cancer therapies.
"Simply put, DNAPrint will utilize computational modeling to develop drugs more efficiently," said DNAPrint President and Chief Executive Officer Richard Gabriel. "It will play a valuable role in our Company's efforts to pursue the development of drugs which maximize efficacy and minimize side effects by tailoring medications for specific individuals and well-defined population sectors."
ben, sounds like they gotta figure out a way to simulate human clinical trials to personalize their EPO drugs.
frog, you are fully aware that EPOFUSION II is in development.
Our Computational Biology Division will be advancing EPOFusion to a second generation model, using knowledge gained in the preclinical phase, for an expanded version (EPOFusion II) used to simulate clinical (human) studies."
You have no access to its' capabilities.
In addition, you can't definitively state what capabilities EPOFUSION has.
Mr. Gabriel said that EPOFusion II will model the molecular and cellular effects of PT-401 so that researchers can ask more "what if" questions about dosage levels and scheduling, as well as the drug's influence on varying patient factors. "The data gathered from these simulations help guide the design of actual clinical trials," he said. "We believe that application of EPOFusion(TM) enhances the potential for successful trials targeted to the right patients with an effective dosing regimen and we anticipate that this will result in reduced time and costs of clinical studies."
Yes, there are many simulation models available. How many are able to personalize findings associated with the "compound"?
You lose...again..
http://209.85.165.104/search?q=cache:oUlRTRFeX-8J:finance.abc7chicago.com/abc%3FID%3D3360381%26Accou...
chaz, Merck is paying $100 million to do that.eom
PIII-35 AN IN-SILICO MODEL FOR PREDICTING THE
ERYTHROPOIETIC RESPONSE TO THE NOVEL EPO
DIMER PT-401.
N. Kabrun, PhD, B. L. Handelin, PhD, H. J. Gomez, MD, PhD,
L. T. Herren, PhD, DNAPrint Genomics, Inc, Sarasota, FL.
53
ASCPT2007Annuall Meettiing
Seventy-Sixth Annual Meeting of the American Association of Physical Anthropologists
to be held at
The Sheraton Society Hill Hotel
Philadelphia, Pennsylvania
March 28 to March 31, 2007
49. Variation in facial features among European populations measured from 3D photographs. D.K. LIBERTON, B. MCEVOY, M. BAUCHET, C.A. HILL, J.T. RICHTSMEIER,
T. FRUDAKIS AND M.D. SHRIVER.
Session 33.
http://www.physanth.org/annmeet/aapa2007/aapa2007schedule.pdf
page 357.
http://books.google.com/books?id=uAf3kDCot9cC&pg=RA2-PA357&lpg=RA2-PA357&dq=%22in+silica...
slog, poor...poor slog....
1. You didn't answer the question.
2. Link and explanation have nothing to do with question.
3. You have no clue what EPOFUSION II does.
DNAPrint Pharmaceuticals Completes the Development of an Analytical Method That Will Be Used for the Development of PT-401
SARASOTA, FL -- (MARKET WIRE) -- July 31, 2006 -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that its subsidiary, DNAPrint Pharmaceuticals, Inc., has completed the development of the so-called "Western blot" method, an analytical procedure that identifies a protein according to its interaction with a specific antibody, a significant step in the development of its PT-401-based proprietary drug to treat anemia.
"The method ensures the identification of PT-401 and meets the requirements of the Food and Drug Administration for a successful Investigational New Drug filing," stated Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint Genomics and the Company's DNAPrint Pharmaceuticals subsidiary.
"The method assures that the development of PT-401 is moving forward," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "We are making excellent progress in developing a successful treatment for anemia."
PT-401 is a "Super EPO," a more powerful form of Erythropoietin, a well-known drug used to treat anemia. PT-401 is a potential competitor in an EPO market that currently exceeds $10 billion and is rapidly growing.
DNAPrint Pharmaceuticals is developing "theranostic" genetic test/drug combinations designed to improve a drug's efficacy and reduce potential side effects. "Our genetic ancestry panel will help identify patient population groups most susceptible to the drug's potential toxic side effects," Mr. Gabriel said. "We believe our genetic ancestry technology offers a distinct, competitive advantage in its application to pharmaceutical development and theranostics. This is where Dr. Frudakis' and our scientific team's work on understanding genetic ancestry will really pay off."
DNAPrint(TM) genomics, Inc.
DNAPrint Genomics is utilizing its EPOFusion™ model to simulate the cellular and molecular dynamics influenced by the administration of the Erythropoietin class of protein drugs in anemia treatments. EPOFusion™ models the interaction of PT-401 -- a novel 2-copy (dimer) form of Erythropoietin -- with the cells that trigger the production of new red blood cells. EPOFusion™ can be manipulated to test hundreds of conditions and variables by simulating what occurs in the whole blood cell production process. The EPOFusion™ model has already identified important differences between PT-401 and currently marketed drugs or drugs in development by other companies. This type of information may provide a competitive advantage and is critical for transparent regulatory filings and effective physician education upon FDA approval of a drug for clinical testing.
http://www.marketwire.com/mw/release_html_b1?release_id=148790&tsource=3
ICEMAN... you chilly, brim... Whadda'ya stinkin'? Is that a Wang in your pocket? Or just a rocket?
2:30 pm Wednesday, March 7, 2007
Applied Computational and Mathematics Seminar: Translational Biomedical Informatics and Systems Biology
by May D Wang (BME, Georgia Tech) in Skiles 255
Dr. Wang has established a translational biomedical informatics and systems biology program, which is integrated with bionanotechnology and lipidomics to solve problems in personalized and predictive oncology. The program consists of (1) identification of diagnostic and prognostic biomarkers from high throughput genomics, proteomics, and lipidomics data, (2) quantification of molecular imaging and profiling data for diagnosis and drug efficacy study, (3) visualization of complex molecular pathways for therapeutics study, as well as (4) interfacing with the National Cancer Institute's Cancer Biomedical Informatics Grid (caBIG). Dr. Wang initiated the integration of biomedical informatics with bionanotechnology and the establishment of several large interdisciplinary programs at Georgia Tech and Emory University BRP (R01CA108468), P20 (P20GM072069), and Emory-Georgia Tech Center of Cancer Nanotechnology Excellence (U54CA119338). This talk will discuss several challenging issues existing in the personalized and predictive medicine field, and opportunities for applying informatics and systems biology approaches.
Submitted by Hao Min Zhou
http://209.85.165.104/search?q=cache:VWEZ7iu5wmoJ:www.math.gatech.edu/cgi-bin/seminar/calendar%3Fyea...
FOR ALL INVESTED:
http://www.siec.k12.in.us/~west/proj/oink/pigs.htm
"THE GOLDEN EGGS"
IMPORTANT CONSIDERATIONS
ZOCOR is a prescription tablet and isn’t right for everyone, including women who are nursing or pregnant or who may become pregnant, and anyone with liver problems. Unexplained muscle pain or weakness could be a sign of a rare but serious side effect and should be reported to your doctor right away. ZOCOR may interact with other medicines or certain foods, increasing your risk of getting this serious side effect. So tell your doctor about any other medications you are taking.
ZOCOR is a registered trademark of Merck & Co., Inc.
http://www.zocor.com/simvastatin/zocor/consumer/product_information/ppi/index.jsp
This is the culmination of a project that was begun when the company was founded," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "It has taken until now to validate the original findings, but validated they are. The Company has filed a patent to protect this process. We plan to bring to market a definitive test product to identify this genetic variant and to potentially prevent painful -- and in some cases, fatal -- side effects in thousands of patients who are taking a very common prescription drug."
DNAPrint's study of 750 patients who had taken either atorvastatin (Lipitor(R)) or simvastatin (Zocor(R)) showed that patients carrying one specific genetic marker were approximately 2.5 times more likely to experience mild to severe muscle pain (myalgia). The effect was most pronounced for atorvastatin and the study showed that approximately one half of the patients who were removed from atorvastatin therapy due to muscle symptoms possess this genetic marker, whereas in the general population (with and without cardiovascular disease) only approximately 15%-25% of people carry the marker. DNAPrint applied its technology for measuring population structure (e.g., ancestry) in order to prove that the finding in both the discovery and validation samples was genuine, and in so doing received praise from JPG reviewers. This observation indicates that the genetic marker may be related not only to response to statins but also to a possible relationship with higher cholesterol levels, according to the study.
"DNA Print Genomics was founded on the underlying genomic screening methods developed to more efficiently scan the genome for medically important genetic markers of drug responses," stated Dr. Frudakis. "The current findings are another example of the efficiency of the Company's methods."
http://www.genengnews.com/news/bnitem.aspx?name=10502612&taxid=27
EMEND (aprepitant) Helps Prevent Nausea/Vomiting for Breast Cancer Patients
the regimen including EMEND (day 1: EMEND 125 mg one hour before chemotherapy, ondansetron 8 mg 30-60 minutes before chemotherapy
EMEND is a registered trademark of Merck & Co
http://www.medicalnewstoday.com/medicalnews.php?newsid=23074
Ondansetron
Through collaboration with the Moffitt Cancer Research Center in Tampa, FL, we are investigating the genetic basis of Ondansetron response. Ondansetron is an anti-emetic for the alleviation of post-operative nausea and vomiting (PONV), but normal doses of the drug do not elicit the desired effect in some patients. A genetic test for predicting Ondansetron response could help reduce extreme discomfort many patients feel after surgery.
March 29, 2004 DNAPrint™ genomics, Inc. Forms Joint Research Program with the H. Lee Moffitt Cancer Center and Research Institute
stockholder, Why don't you correct all the errors in that e-mail. It pains me to look at them. "dnap"...the Moffett..etc...Better yet, send it back and tell'em to get their act together. Remember...we do own the company!
Thanks Brother. We lose sight of how this could effect so many lives. Save life. Good Luck, Brother..
Ancestry for fish! Too much..
Applications of SNP Genotyping in
Fisheries Management
Girdwood, Alaska September 21–22, 2006
Discovering and Using Linked and Unlinked
SNPs for Population Genetic Inference
http://www.genetics.cf.adfg.state.ak.us/workshop/AbstractFinal.pdf
THURSDAY!! HAH!!HAH!!EOM
altar, It was a bad idea for me to start speculating on the restructuring of the company. There are too many variables with multiple outcomes. Here are some numbers to consider:
DNAPRINT GENOMICS INC (DNAG)
Form: 10QSB
Filing Date: 11/13/2006
September 30, 2006
Convertible notes ** 229,430,066
Convertible preferred stock ** -
Warrants and options 93,719,795
323,149,861
http://yahoo.brand.edgar-online.com/fetchFilingFrameset.aspx?FilingID=4757816&Type=HTML
The amount in bold is total shares that can be converted to common.
As you can see, they've already converted all of their preferred. The holders have given them up for common shares. This is typical for recapitalization of the company.
The notes and options,323,149,861, that can be converted to common, certainly expound the risk-effect on the PPS.
31,585,212 This # is what the company has of paid-in capital.
DNAG also received $5.9 million from sale of Bio stock.
Venture capital would insist that anti-dilutive measures be taken. They are not going to invest money in the company with the possibility of these shares diluting equity.
The float is 417 million.
Good Luck to All this week!!
frogdreaming, that post will go down as a "Classic"
I asked:
Why don't you tell the board what you believe will be the outcome of PT-401. Don't run away.. I'm waiting.
Your answer:
We will probably never know the 'outcome'. In order to have an 'outcome' we need the process to be initiated.
Absolutely, brilliant!!
quohogue,
This technology will be very useful for population stratification, and will serve as an extremely important quality control, particularly for large scale case control genetic association studies. Additionally, it will provide benefits in other areas, including pharmacogenetics," said Dr. Mark Bouzyk, Director of Emory's Center for Medical Genomics.
I'm sorry that all you have learned to date about "STANDARDS AND PRACTICES FOR VALIDATION" is about to be thrown out the window. I'm sure Emory, DnaPrint, and the FDA will have a new manual out soon.
Collaboration ultimately leads to validation...collaboration is the only validation when parameters of the unknown need to be set; new technology, not incorporated yet in standard practices....you do understand that...don't you?
By the way, we don't pay anybody to use our platform at Emory.
It's a "collaborative agreement" that will help in validating the platform with the FDA. In fact, MK-0518 will also be fast-tracked.
sam, things are happening very fast. Does anybody else here believe the pharmaceutical industry is about to get an overhaul? Are we a big player?
prod, why does FDA think this:
Next step is a good strategy (that includes interactions
with FDA…) to (co-)develop drugs and/or tests )
This is not a vision, but happening today – oncology is
one of the main focus areas
You can throw out your FDA "STANDARDS AND PRACTICES MANUAL" over there in Enginering...it's outdated. Case closed...ROTFL
What the FDA thinks:
Obviously they didn't cc frog on this. The new standards at the FDA have already been outlined. All alone on the lily pad...left out of the loop again...
Pharmacogenomics and genomic biomarkers
– Definition
– Validation (pre-clinical biomarkers for safety)
Summary
Pharmacogenomics: biomarker and tool to measure it
Biomarkers: pre-requisite for personalized/ targeted
medicine (and there are more than genomic BMs)
Validation of biomarker is a critical step with scientific
as well as regulatory implications
http://www.fda.gov/cder/genomics/PGX_biomarkers.pdf